Showing 890 – 900 of 1307 results
-
Resideo Technologies Inc Initiation
William Blair & Company initiated research coverage of Resideo Technologies, Inc. (REZI $25.69), a global manufacturer and distributor of smart home products for comfort, security, and energy efficiency.
-
Paya Holdings Inc Initiation
William Blair & Company initiated research coverage of Paya Holdings Inc. (PAYA $13.49), a provider of software-led, digital payments capabilities to over 100,000 merchants in the United States.
-
JOANN Inc Initiation
William Blair & Company initiated research coverage of JOANN Inc. (JOAN $10.99), the largest retailer of sewing products and accessories in the United States and a large and growing player in the arts and crafts category.
-
Karat Packaging Inc Initiation
William Blair initiated research coverage of Karat Packaging, Inc. (KRT $17.37), a fast-growing manufacturer and distributor of environmentally friendly, single-use disposable products, primarily used in restaurants and foodservice settings.
-
Accolade Inc Initiation
William Blair & Company initiated research coverage of Accolade, Inc. (ACCD $32.94), one of the largest providers of benefit management solutions in the United States.
-
JFrog Ltd Initiation
William Blair & Company initiated research coverage of JFrog, Ltd. (FROG $73.37), a provider of DevOps solutions to developers and enterprises around the world.
-
Codiak BioSciences Inc Initiation
William Blair & Company initiated research coverage of Codiak BioSciences, Inc. (CDAK $9.06). Based in Cambridge, Massachusetts, the company is developing a novel exosome based drug platform with lead programs in cancer immunotherapy.
-
Atea Pharmaceuticals Inc Initiation
William Blair & Company initiated research coverage of Atea Pharmaceuticals, Inc. (AVIR $33.17), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics.
-
Aravive Inc Initiation
William Blair & Company initiated research coverage of Aravive, Inc. (ARAV $5.81), a clinical-stage biotechnology company that leverages deep insights into essential cancer signaling pathways. The company’s lead asset AVB-500 completed a Phase Ib study earlier this year, and will soon enter midstage trials in ovarian and kidney cancer.
-
Vertex Pharmaceuticals Incorporated Initiation
William Blair initiated research coverage of Vertex Pharmaceuticals Incorporated (VRTX $332.63), a biopharma company focused on the development and commercialization of transformative specialty medicines for the treatment of cystic fibrosis (CF) and other rare genetic diseases.